News

BioXcel Therapeutics Secures Grant for BXCL501 Study in Stress Relief

BioXcel Therapeutics Secures Grant for BXCL501 Study in Stress Relief

Exciting Development in Mental Health Treatment

In a groundbreaking collaboration, BioXcel Therapeutics, Inc. (NASDAQ: BTAI) has joined forces with the University of North Carolina at Chapel Hill (UNC) thanks to a substantial grant from the U.S. Department of Defense. This grant aims to explore the effectiveness and safety of BXCL501, a novel treatment for acute stress disorder (ASD).

Understanding the Impact of Acute Stress Disorder

Each year, approximately 40 million Americans seek emergency care due to traumatic experiences. ASD can manifest symptoms such as anxiety, sleep disturbances, and physical pain shortly after trauma. If unresolved, these symptoms can evolve into more chronic forms, including post-traumatic stress disorder and depressive disorders.

Details of the Research Initiative

The U.S. Department of Defense granted $2.8 million to the UNC Institute for Trauma Recovery, designated for a research period from late 2024 until 2026. The study will aim to assess BXCL501’s potential in alleviating ASD symptoms in individuals involved in motor vehicle accidents. Enrollment for this phase 2a clinical trial is set to commence in early 2025, with BioXcel providing the therapeutic agent for the study.

Expert Insights on BXCL501

Dr. Samuel McLean, the principal investigator and Professor of Psychiatry, emphasizes the crucial need for effective early interventions for ASD. He expresses optimism about BXCL501's use in providing immediate relief to patients suffering from acute stress reactions, thereby decreasing the risk of chronic symptom development.

BXCL501: A Promising Therapeutic

BXCL501, also known as IGALMI™, is an investigational oral formulation of dexmedetomidine, commonly recognized for its therapeutic applications in various psychiatric conditions. The FDA has already acknowledged its capability by granting it Breakthrough Therapy status. This recognition underscores its potential to reshape treatment strategies for agitation related to disorders such as Alzheimer’s dementia, schizophrenia, and bipolar disorders.

Other Supported Research Initiatives

The recently announced trial at UNC represents just one aspect of BioXcel's broader research agenda. The company is actively pursuing several investigator-initiated trials focused on post-traumatic stress disorder (PTSD), opioid use disorder (OUD), and alcohol use disorder (AUD). Collaborative projects at leading institutions like Yale and Columbia are underway to enhance treatment modalities for these debilitating conditions.

BioXcel Therapeutics' Vision for the Future

BioXcel Therapeutics is a biopharmaceutical entity leveraging artificial intelligence to innovate treatments within neuroscience. Their unique approach revolves around navigating untapped potential in existing drug therapies, employing data-driven methodologies to redevelop substances for new indications.

Corporate Communication and Future Opportunities

Both corporate and media inquiries can be directed to BioXcel's contact points for further discussions related to ongoing studies and developments. As the landscape of mental health treatment evolves, BioXcel stands at the forefront, committed to pioneering solutions that could fundamentally alter treatment paradigms.

Frequently Asked Questions

What is the purpose of the study with BXCL501?

The study aims to evaluate the efficacy and safety of BXCL501 for treating acute stress disorder resulting from trauma such as motor vehicle accidents.

How many patients will participate in the BXCL501 trial?

The trial is expected to enroll 100 patients experiencing acute stress disorder.

What is BXCL501 used for beyond acute stress disorder?

BXCL501 is also being explored for its potential to treat agitation in conditions such as bipolar disorder, schizophrenia, and Alzheimer’s dementia.

Who is leading the research study?

The study is being led by Dr. Samuel McLean, a respected expert in psychiatry from the University of North Carolina.

What is the timeline for the trial?

Enrollment for the study is anticipated to begin in the first half of 2025, following the grant period for the research.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 138

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 113

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 161

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
CustomerInsights.AI Fast 500 Nod Tests Its AI Model

Updated Category News Views 44

Pharma’s analytics mess is exactly where CustomerInsights.AI has chosen to make its stand. The Scottsdale company’s inclusion in Deloitte’s 2026 Technology Fast 500, announced November 19, is a useful signal that its pitch is finding buyers: life-sciences businesses want AI to do actual commercial work, not sit in a lab demo collecting dust. Still, a Fast 500 badge...

Continue Reading
Mimic Bets Virtual Patching Can Calm AI Patch Chaos

Updated Category News Views 16

Three ugly outages in four days can make even hardened technology buyers reconsider the sacred ritual of “patch immediately.” Mimic’s new Virtual Patching offering arrives squarely in that uncomfortable gap: a vulnerability is known, attackers may be moving fast, and the proper vendor update still needs testing before somebody detonates production. The company’s...

Continue Reading
Miami Office Puts Dubai Closer to U.S. Business Deal Flow

Updated Category News Views 68

Miami is not a random pin on a map; it is a deliberate front door to the Americas, and Dubai International Chamber has decided it needs someone standing in it. The chamber opened a representative office there on November 19, 2026, its second in the United States after launching in New York during the Dubai Business Forum – USA in November 2025. This is not the sort of...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 118

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading
Eight O'Clock Adds Blonde Roast Pods to Its Lineup

Updated Category News Views 144

A lighter cup of coffee just became Eight O'Clock Coffee's newest swing at the single-serve shelf. On Nov. 19, 2026, the company said it introduced Blonde Roast K-Cup pods, a bright and smooth option aimed at drinkers who prefer a lighter roast. The product is available through Keurig.com and Amazon. That is the whole announcement, and frankly it is better to keep it that...

Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 53

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 102

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading

Top 5 Most Recently Viewed Articles

Orion Unveils New Wealth Management Tools for Advisors

Updated Category News Views 212

Orion Unveils New Wealth Management Tools for Advisors Orion, known for empowering financial advisors with cutting-edge wealth management solutions, is excited to announce a series of significant enhancements aimed at assisting advisors in servicing high-net-worth (HNW) and ultra-high-net-worth (UHNW) clientele. As new economic paradigms shift with generational wealth...

Continue Reading
Myriad Genetics Enhances Breast Cancer Research with Collaborations

Updated Category News Views 119

Myriad Genetics Expands Research Collaborations for Breast Cancer Testing Myriad Genetics, Inc. (NASDAQ: MYGN), a pioneer in genetic testing and precision medicine, has recently embarked on a series of important research collaborations aimed at studying the application of molecular residual disease (MRD) testing in breast cancer. These initiatives leverage Myriad’s...

Continue Reading
Man Group PLC Discloses Significant Position in American Axle

Updated Category News Views 158

Significant Position Disclosure by Man Group PLC Man Group PLC, a global investment management firm, has made a notable disclosure concerning its significant interests in American Axle & Manufacturing Holdings, Inc. This disclosure falls under Rule 8.3 of the UK Takeover Code, which mandates disclosure by entities holding 1% or more of relevant securities in any company...

Continue Reading
Legal Protection Steps for Jasper Therapeutics Investors

Updated Category News Views 223

Understanding the Importance of Legal Counsel Deciding to invest in a company like Jasper Therapeutics, Inc. (NASDAQ: JSPR) can be a significant move, but it's crucial to be aware of the potential challenges that come with investing in securities. Individuals who have bought shares in Jasper Therapeutics between certain dates should pay close attention to upcoming...

Continue Reading
TotalEnergies Expands on Gas Strategy with Latest Acquisition

Updated Category News Views 124

TotalEnergies Expands on Gas Strategy with Latest Acquisition TotalEnergies SE (TTE) shares have shown an upward trend, particularly in premarket trading. Recently, the company announced a notable agreement with Lewis Energy Group that involves acquiring a significant 45% stake in its dry gas-producing assets located in the Eagle Ford Basin, Texas. Details of the...

Continue Reading